Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Liraglutide on fatty liver content in patients with type 2 diabetes
2012-000375-16Phase 4Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Feb 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of liraglutide in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Feb 2012; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2012-000375-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000375-16.